Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb 13:13:60.
doi: 10.1186/1472-6963-13-60.

Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases

Derek Weycker  1 , Oleg Sofrygin, Kim Seefeld, Robert G Deeter, Jason Legg, John Edelsberg
Affiliations

Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases

Derek Weycker et al. BMC Health Serv Res. .

Abstract

Background: Healthcare claims databases have been used in several studies to characterize the risk and burden of chemotherapy-induced febrile neutropenia (FN) and effectiveness of colony-stimulating factors against FN. The accuracy of methods previously used to identify FN in such databases has not been formally evaluated.

Methods: Data comprised linked electronic medical records from Geisinger Health System and healthcare claims data from Geisinger Health Plan. Subjects were classified into subgroups based on whether or not they were hospitalized for FN per the presumptive "gold standard" (ANC <1.0×10(9)/L, and body temperature ≥38.3°C or receipt of antibiotics) and claims-based definition (diagnosis codes for neutropenia, fever, and/or infection). Accuracy was evaluated principally based on positive predictive value (PPV) and sensitivity.

Results: Among 357 study subjects, 82 (23%) met the gold standard for hospitalized FN. For the claims-based definition including diagnosis codes for neutropenia plus fever in any position (n=28), PPV was 100% and sensitivity was 34% (95% CI: 24-45). For the definition including neutropenia in the primary position (n=54), PPV was 87% (78-95) and sensitivity was 57% (46-68). For the definition including neutropenia in any position (n=71), PPV was 77% (68-87) and sensitivity was 67% (56-77).

Conclusions: Patients hospitalized for chemotherapy-induced FN can be identified in healthcare claims databases--with an acceptable level of mis-classification--using diagnosis codes for neutropenia, or neutropenia plus fever.

PubMed Disclaimer

References

    1. Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L. et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ. 2005;330(7485):217. doi: 10.1136/bmj.38314.622095.8F. - DOI - PMC - PubMed
    1. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21(24):4524–4531. doi: 10.1200/JCO.2003.05.002. - DOI - PubMed
    1. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L. et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187–3205. doi: 10.1200/JCO.2006.06.4451. - DOI - PubMed
    1. Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol. 1990;8(6):963–977. - PubMed
    1. Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P. International Pegfilgrastim 749 Study Group et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration Pegfilgrastim versus daily Filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14:29–35. doi: 10.1093/annonc/mdg019. - DOI - PubMed

Publication types

Substances